Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7624612 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL854090 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL1773132 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL7612611 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL7563162 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL11806608 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL2404356 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL79441 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL17027772 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL3310359 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113121579-B | Synthesis method of 3- (6-phenylhexyl) phenylboronic acid and derivative thereof | 河北松辰医药科技有限公司 | 2023-06-06 | — | — | CN | claimed |
| US-12607789-B2 | Display panel and method of manufacturing the same and electronic device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2026-04-21 | — | — | US | disclosed |
| US-20250311610-A1 | COPOLYMER, AND COMPOSITION, LIQUID COMPOSITION, AND ELECTROLUMINSECNT DEVICE INCLUDING THE COPOLYMER | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-10-02 | — | — | US | disclosed |
| EP-4624510-A1 | COPOLYMER, COMPOSITION, LIQUID COMPOSITION, AND ELECTROLUMINSECNT DEVICE INCLUDING THE COPOLYMER | Samsung Electronics Co., Ltd. (KR) | 2025-10-01 | — | — | EP | disclosed |
| CN-115850002-B | Method for hydrodehalogenating halogenated alkane | 中国科学院兰州化学物理研究所 | 2025-05-23 | — | — | CN | disclosed |
| WO-2024140595-A1 | TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-112625502-B | Ink composition, quantum dot-polymer composite, display device, and method of manufacturing the same | 三星显示有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-114716296-B | Efficient halogenation synthesis method of alkyl halide | 润药仁智(北京)科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-115108973-B | Electrically neutral ionic liquid and preparation method thereof | 苏州旭珀禾科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-3983158-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3980694-A | ANTIULCER, ANTIAGGLOMERANTS, INCREASE OF NASAL PATENCY, LABOR INDUCEMENT, WOUND HEALINGPROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-09-14 | — | — | US | disclosed |
| US-3944595-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1976-03-16 | — | — | US | disclosed |
| US-3933898-A | ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3933897-A | ANTIULCER, ASTHMA, RENAL DYSFUNCTION | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3933896-A | ANTICOAGULANTS, ASTHMA, LABOR INDUCERS, CERVICAL DILATION | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3933900-A | ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3933899-A | ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3933895-A | PROSTAGLANDINS, ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3931289-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12607789-B2 | Display panel and method of manufacturing the same and electronic device | CD63, CD2, NECTIN4 | TDP1 2378/4885SIGMAR1 2867/4885MAOA 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.